NEW YORK (GenomeWeb News) – Ferrer inCode, the biotech subsidiary of Spanish firm Grupo Ferrer, has gained exclusive rights to sell two of Agendia’s cancer diagnostic services in certain European countries, the firms said today.
Ferrer will offer Agendia’s MammaPrint and CupPrint tests in Germany, France, Italy, and Portugal. Ferrer already sells the tests in Spain under an agreement signed last year.
MammaPrint is a prognostic, gene expression profiling test that uses 70-gene signature to indicate the risk of breast cancer tumor recurrence. CupPrint is a gene expression profiling service that is used to identify the primary tumor site in cancer of unknown primary.
The firms said that they are discussing a potentially expanded deal to include other parts of the world.